Jewish General Hospital
Montreal, Quebec, H3T 1E2, Canada
NCT Number: NCT03698760
This study evaluates the effectiveness of the smell tests that are used in early diagnosis of mild dementia.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Not applicable
Montreal, Quebec, H3T 1E2, Canada
For twenty years research has shown a strong link between olfactory disorders and Alzheimer's disease. The focus is on the very early alteration of the olfaction which acts as a harbinger of the disease since it is detectable in its asymptomatic phase. In addition, olfactory involvement is a precursor to the transformation of mild cognitive impairment into MA. Indeed the anatomical structures the first lesions are located in the transentorhinal region of the temporal lobe and entorhinal phase, before progressing towards the limbic system, which will mark the clinical appearance of the first signs of AD.
In literature, it has been shown that there was no olfactory test that is recognized as a gold standard in the scientific community due to a lack of homogeneity of the tools used, their availability and their validity depending on the culture. Moreover, of all the tests currently available, none are specific to neurodegenerative diseases.
Very recent studies show that there is also a strong preference for imaging tools or biomarkers in the detection of AD, but it appears that the olfactory disorders are well before these markers. It has been shown that an identification test is comparable in predictive accuracy to neuroimaging and cerebrospinal fluid sampling.
This study will therefore focus on the calibration and validation of a computerized olfactory test for the diagnosis of Alzheimer's disease and based the recommendations of professionals so as to promote the effective use of this test in clinical practice.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Olfactory test:
All fragrances tested are kept in an airtight case protected from cold and heat.
The test is done on a tablet and the data will be automatically saved. The first screen is about the administrative data, sex and age of the subject. Olfactory test: six odors among the fourteen are proposed in a randomized way.
Time frame: 15 minutes
olfactory test (only one evaluation): random fragrances, recognition (Yes or No)
Time frame: 10 minutes
self-administered questionnaire (SAQ), score between 0 and 18, a higher score means a higher frailty
Time frame: 15 minutes
olfactory test, 6 random fragrances among 14, recognition Yes or No and at what concentration
Jewish General Hospital
Other
Calibration and Validation of a Computerized Olfactory Test in Subjects With Alzheimer's Disease in a Mild Stage
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01951118
Alzheimer Disease, Anosmia
New York, United States
View Trial DetailsNCT07021040
Alzheimer Disease, Anosmia
Durham, North Carolina, United States
View Trial DetailsNCT06347172
Alzheimer Disease, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial Details